OTCMKTS:HBPCF Helix Biopharma (HBPCF) Stock Price, News & Analysis $1.71 0.00 (0.00%) As of 08/7/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsShort InterestBuy This Stock About Helix Biopharma Stock (OTCMKTS:HBPCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix Biopharma alerts:Sign Up Key Stats Today's Range$1.71▼$1.7150-Day Range$1.71▼$1.7152-Week Range$1.71▼$1.73VolumeN/AAverage Volume1 shsMarket Capitalization$130.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Helix BioPharma Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies. Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe. The company’s integrated R&D infrastructure supports early‐phase clinical trials, biomarker discovery, formulation development and manufacturing scale‐up, reflecting its commitment to rigorous scientific validation and regulatory compliance. Governed by a management team with extensive experience in oncology research, drug development and biopharmaceutical operations, Helix BioPharma continues to advance its immunotherapy pipeline toward commercialization milestones. The company actively explores strategic partnerships and licensing opportunities to broaden the geographic reach of its investigational therapies and address unmet medical needs worldwide.AI Generated. May Contain Errors. Read More Receive HBPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBPCF Stock News HeadlinesHelix BioPharma Files Interim Financial Statements for April 2025June 16, 2025 | tipranks.comHelix BioPharma Appoints New CFO to Drive Strategic GrowthJune 2, 2025 | tipranks.comSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.August 10 at 1:00 AM | Freedom Financial (Ad)Helix BioPharma Secures $13 Million Financing to Advance Cancer TherapiesMay 14, 2025 | tipranks.comHelix BioPharma Appoints New CEO to Propel Clinical AdvancementsApril 10, 2025 | tipranks.comHelix BioPharma Engages ITG for Market-Making ServicesApril 3, 2025 | tipranks.comHelix BioPharma Corp. Announces Key Decisions from Annual MeetingMarch 26, 2025 | tipranks.comHelix BioPharma Releases Interim Financial Statements for January 2025March 18, 2025 | tipranks.comSee More Headlines HBPCF Stock Analysis - Frequently Asked Questions How have HBPCF shares performed this year? Helix Biopharma's stock was trading at $1.7338 at the beginning of the year. Since then, HBPCF stock has decreased by 1.4% and is now trading at $1.71. How were Helix Biopharma's earnings last quarter? Helix Biopharma Corp. (OTCMKTS:HBPCF) issued its quarterly earnings data on Friday, June, 12th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.07. How do I buy shares of Helix Biopharma? Shares of HBPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/12/2026Today8/10/2026Next Earnings (Estimated)10/29/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:HBPCF CIKN/A Webwww.helixbiopharma.com Phone905-841-2300Fax905-841-2244Employees9Year Founded1995Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.61% Return on Assets-17.14% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book11.40Miscellaneous Outstanding Shares76,380,000Free Float70,577,000Market Cap$130.61 million OptionableNot Optionable Beta0.17 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:HBPCF) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...Awesomely | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredEric Fry’s super simple investing mantraFormer Wall Street money manager Eric Fry used a simple four-word mantra to win a major financial competition,...InvestorPlace | SponsoredI found Rolls-Royce below $2. Now THIS.In 2022, Karim Rahemtulla flagged Rolls-Royce when shares traded below $2 - they later climbed above $10. N...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix Biopharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
